CoChat

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 3 of the 18 sources its claims cite were checked for support.

Abstract

BACKGROUND: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). Transient cardiovascular stimulatory effects have been reported with ketamine. METHODS: Cardiovascular effects of esketamine nasal spray, combined with an oral antidepressant, were evaluated in 1708 esketamine-treated adults with TRD in six trials (five double-blind, placebo-controlled (486 placebo-treated patients); one open-label) of 4-52 weeks' duration. Patients with established cardiovascular disease, including uncontrolled hypertension (> 140/> 90 mmHg), history of hypertensive crisis, or clinically significant electrocardiogram (ECG) abnormalities, were excluded from enrollment. Effects on cardiac repolarization were assessed in a phase I randomized, positive- and active-controlled thorough corrected QT (QTc) interval study. For adverse events, odds ratio (OR) [95% confidence interval] for esketamine/antidepressant versus antidepressant/placebo was calculated. RESULTS: Adverse events related to increased BP were reported in 12.8% of all esketamine-treated patients (in double-blind trials: esketamine/antidepressant 11.6% vs. antidepressant/placebo 3.9%; OR 3.2 [1.9-5.8]). Among the patients without a history of hypertension, new antihypertensive medication was initiated by 2.1% (6/280) of patients in the esketamine/antidepressant group versus 1.2% (2/171) of patients in the antidepressant/placebo group, in the double-blinded studies. Adverse events related to abnormal heart rate were reported in 3.0% of all esketamine-treated patients (in double-blind trials: 1.6% vs. 0.8%; OR 1.9 [0.5-8.6]). Overall, three cardiovascular adverse events related to BP increase were reported as serious and severe, and there was one fatal event considered unrelated (acute cardiac failure). BP increases reached the maximum postdose value within ~ 40 min of esketamine dosing and returned to the predose range by ~ 1.5 h postdose. In two studies (4-week duration, age 18-64 years), the largest mean maximum systolic/diastolic postdose BP increases were 13.3/8.7 mmHg for esketamine/antidepressant and 6.1/4.9 mmHg for antidepressant/placebo, and in a short-term elderly study (age ≥ 65 years) were 16.0/9.5 and 11.1/6.8 mmHg, respectively. Across studies/study phases, < 2% of patients discontinued esketamine due to adverse events of increased BP and tachycardia. No clinically relevant effect on ECG parameters was observed. Therapeutic and supratherapeutic doses of esketamine did not prolong the QTcF (QT corrected by Fridericia's equation) interval (baseline-corrected values of - 2.02 to 2.16 ms, and - 3.51 to 4.89 ms, respectively). CONCLUSIONS: BP elevations following esketamine dosing are generally transient, asymptomatic, and not associated with serious cardiovascular safety sequalae. Further evaluation of long-term cardiovascular outcomes is warranted.

Overview

CoChat Summary

TL;DR

In six trials of esketamine nasal spray plus an oral antidepressant in treatment-resistant depression (1708 esketamine-treated, 486 placebo-treated), blood pressure increases were common but generally transient, asymptomatic, and not linked to serious cardiovascular sequelae. No clinically relevant effect on ECG parameters or QTcF was observed, though long-term cardiovascular outcomes remain unknown.

Key findings

  • Increased BP-related adverse events occurred in 12.8% of all esketamine-treated patients; in double-blind trials, 11.6% with esketamine/antidepressant vs 3.9% with antidepressant/placebo (OR 3.2 [95% CI 1.9–5.8]). Most were mild or moderate (98%) and resolved (94%).
  • Abnormal heart rate-related adverse events occurred in 3.0% of all esketamine-treated patients; in double-blind trials, 1.6% vs 0.8% (OR 1.9 [95% CI 0.5–8.6]), with 96% mild/moderate and 88% resolved.
  • BP increases peaked within ~40 min of dosing and returned to predose range by ~1.5 h. Largest mean maximum SBP/DBP increases were 13.3/8.7 mmHg for esketamine/antidepressant vs 6.1/4.9 mmHg for antidepressant/placebo in 18–64-year-olds, and 16.0/9.5 vs 11.1/6.8 mmHg in elderly patients. Discontinuation due to increased BP and tachycardia was <2% across studies/phases.
  • Therapeutic and supratherapeutic esketamine did not prolong QTcF: baseline-corrected values ranged from −2.02 to 2.16 ms and −3.51 to 4.89 ms, respectively, below the 10 ms ICH E14 threshold. Three serious and severe BP-related cardiovascular adverse events were reported in two patients; one fatal event of acute cardiac failure was considered unrelated.

Methods

  • Pooled cardiovascular safety analysis from five double-blind, placebo-controlled phase II/III studies and one open-label phase III study of esketamine nasal spray plus oral antidepressant in adults with TRD; 1708 esketamine-treated and 486 placebo-treated patients, 4–52 weeks’ duration. Patients with established cardiovascular disease, uncontrolled hypertension (>140/>90 mmHg), history of hypertensive crisis, or clinically significant ECG abnormalities were excluded.
  • Assessments included adverse events, vital signs, and ECG monitoring; BP and pulse/heart rate were measured at baseline and dosing visits. A phase I randomized, positive- and active-controlled thorough QTc study used oral moxifloxacin 400 mg as positive control and esketamine 84 mg nasal spray and 0.8 mg/kg IV infusion.
  • For adverse events, odds ratios with two-sided exact 95% CIs were calculated for esketamine/antidepressant vs antidepressant/placebo in the All Randomized, Blinded Trials TRD Population; other analyses were descriptive.

Limitations

  • Stated: generalizability may be limited by exclusion of patients with cardiovascular disease within 12 months before trial start, uncontrolled hypertension at enrollment, or clinically significant ECG abnormalities; BP elevations or ECG changes between dosing sessions were not routinely documented; long-term effects of repeated transient BP increases lasting 1–4 h are unknown, and further long-term cardiovascular outcome monitoring is warranted.
  • Evident from the text: the safety analyses are largely descriptive outside the double-blind adverse-event odds ratios, and the long-term open-label study contributes substantial exposure data without a parallel control group, limiting causal inference for rare or long-term cardiovascular events.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40263-020-00699-4

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Mean [± standard error (SE)] blood pressure over time from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]
Fig. 1 Mean [± standard error (SE)] blood pressure over time from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]CC BY-NC · PubMed Central
Fig. 2 Mean maximum [± standard error (SE)] and maximum change in postdose blood pressure: pooled results from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]
Fig. 2 Mean maximum [± standard error (SE)] and maximum change in postdose blood pressure: pooled results from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18–64 years [5, 6]CC BY-NC · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 13 Not checked · 59 Own results and interpretations

42 more claims

Create a free account to see all 73 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 20 references

Cited by

See all 68

Metadata

Authors
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A.
Affiliations
  • Janssen Research & Development (United States) (US)
  • Janssen (Belgium) (BE)
  • Neurocrine Biosciences (United States) (US)
  • SUNY Downstate Health Sciences University (US)
Corresponding author
Doherty, Teodora
Venue
CNS Drugs
Published
2020-01-29
Volume
34
Issue
3
Pages
299-310
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W3004365315
Cited by
68
References
20
Citations by year
2026: 14 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 13 · 2021: 12 · 2020: 9
FWCI
6.30
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Janssen Research and Development, LLC, Titusville, NJ, USA
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords
esketamine nasal spray, treatment-resistant depression, cardiovascular safety, blood pressure increase, heart rate increase, QTc interval, cardiac repolarization, hypertension, adverse events, antidepressant combination therapy, ketamine
MeSH terms
Administration, Intranasal, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Double-Blind Method, Female, Heart, Humans, Ketamine, Male, Middle Aged, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Young Adult, Nasal Sprays, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. https://app.cochat.ai/papers/10.1007/s40263-020-00699-4
The paper
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020). Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs. https://doi.org/10.1007/s40263-020-00699-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.